CURR looks like its is offering an excellent point for new entry and/or accumulation with all the earnings potential that is reflected in the company's current business plan and news announcements.
The recent trading pattern is also showing us how easily CURR can move up when new investors discover the advanced products, marketing programs and overall growth story here. This is a very good time to take a close look at all the company has in play for 2020 and beyond.
About CURE Pharmaceutical CURE Pharmaceutical® is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and patient experience through its proprietary drug dosage forms and delivery systems. CURE has an FDA- and DEA- registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform. CUREform includes CUREfilm®, one of the most advanced oral thin films on the market today; microCURE™, an innovative emulsion technology utilizing proprietary encapsulation techniques; and CUREpods™ a novel chewable delivery system. CUREform's combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S, Canada, Israel, and other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at http://www.curepharma.com.
News 
Market Data 
Discover 
